Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2008
05/02/2008WO2007105115A3 Compositions and methods for immunisation using cd1d ligands
05/02/2008WO2007098436A3 Platelet stabilization
05/02/2008WO2007097989A3 A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
05/02/2008WO2007095462A3 Compounds for the treatment of metabolic disorders
05/02/2008WO2007095342A9 Stable corticosteroid mixtures
05/02/2008WO2007081569A3 Cetp inhibitors
05/02/2008WO2007064762A3 Conjugates of amino acids and vitamin b3 for percutaneous delivery of vitamin b3
05/02/2008WO2007061868A3 Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
05/02/2008WO2007056331A3 Compositions and methods for inhibiting expression of factor v leiden mutant gene
05/02/2008WO2007056214A8 N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
05/02/2008WO2007030776A3 Method of supporting and/or applying particulate materials
05/02/2008WO2007027548A3 Methods of modulating intestinal fluid balance
05/02/2008WO2005084329A8 Method for inhibiting tumor formation and growth
05/02/2008WO2005013885A3 Pharmaceutical compositions and methods for accelerating wound healing
05/02/2008CA2703646A1 Peptide vaccine for influenza virus
05/02/2008CA2669117A1 Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
05/02/2008CA2669111A1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
05/02/2008CA2667816A1 Compositions and methods for inhibiting cathepsin proteases
05/02/2008CA2667582A1 Method of treating conditions associated with proteoglycan production
05/02/2008CA2667553A1 Methods and combination therapies for treating alzheimer's disease
05/02/2008CA2667550A1 Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
05/02/2008CA2667548A1 Substituted piperidyl-propane-thiols
05/02/2008CA2667547A1 Piperidyl-propane-thiol ccr3 modulators
05/02/2008CA2667545A1 Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
05/02/2008CA2667543A1 New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders
05/02/2008CA2667507A1 Trypsin-like serine protease inhibitors, and their preparation and use
05/02/2008CA2667453A1 Triazolo-pyridazine protein kinase modulators
05/02/2008CA2667435A1 Chemical compounds
05/02/2008CA2667428A1 Bicyclic triazoles as protein kinase modulators
05/02/2008CA2667416A1 Process for making crystalline anhydrous docetaxel
05/02/2008CA2667397A1 Oleanane triterpene saponin compounds which are effective on treatment of dementia and mild cognitive impairment (mci), and improvement of cognitive function
05/02/2008CA2667363A1 Discontinuous methods of treating cancer
05/02/2008CA2667362A1 Methods of treating ovarian cancer
05/02/2008CA2667316A1 Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators
05/02/2008CA2667231A1 Process for selectively localizing active ingredients on and in mitochondria and corresponding active ingredients
05/02/2008CA2667207A1 Ibuprofen composition
05/02/2008CA2667197A1 Salt forms of substituted benzothienyl compounds
05/02/2008CA2667176A1 Therapeutic agent for irritable bowel syndrome
05/02/2008CA2667146A1 Hcv ns3 protease inhibitors
05/02/2008CA2667052A1 Combination therapy
05/02/2008CA2667007A1 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
05/02/2008CA2667003A1 Substituted imidazoles as bombesin receptor subtype-3 modulators
05/02/2008CA2667002A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment
05/02/2008CA2666973A1 Indole compound having a glucokinase activating action
05/02/2008CA2666965A1 Crystal modifications of -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-dione
05/02/2008CA2666940A1 Purines as pkc-theta inhibitors
05/02/2008CA2666936A1 Method of preventing or treating metabolic syndrome
05/02/2008CA2666925A1 Combination therapy for the treatment of pain
05/02/2008CA2666922A1 Novel heteroaryl carboxamides
05/02/2008CA2666885A1 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
05/02/2008CA2666846A1 Method of restoring the incretin effect
05/02/2008CA2666670A1 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
05/02/2008CA2666624A1 Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
05/02/2008CA2666618A1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith
05/02/2008CA2666606A1 Preventing or reducing oxidative stress or oxidative cell injury by the administration of a water-insoluble cellulose derivative
05/02/2008CA2666582A1 Acetaminophen / ibuprofen combinations
05/02/2008CA2666539A1 Substituted phenylmethyl bicyclocarboxyamide compounds
05/02/2008CA2666538A1 Use of citrulline for treating undernutrition conditions
05/02/2008CA2666522A1 Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
05/02/2008CA2666512A1 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
05/02/2008CA2666497A1 Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
05/02/2008CA2666482A1 Soluble epoxide hydrolase inhibitors
05/02/2008CA2666350A1 Isolated hydroxy and n-oxide metabolites and derivatives of o-desmethylvenlafaxine and methods of treatment
05/02/2008CA2666197A1 Novel vitamin d2 yeast preparation, a method for producing the same, and the use thereof
05/02/2008CA2665736A1 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
05/02/2008CA2665710A1 Ih channel inhibitors for the promotion of wakefulness
05/02/2008CA2665024A1 Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
05/02/2008CA2664794A1 Substituted imidazoles as bombesin receptor subtype-3 modulators
05/02/2008CA2664347A1 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as p2y12 receptor antagonists
05/02/2008CA2664165A1 Use of mtki 1 for treating or preventing bone cancer
05/02/2008CA2664148A1 Vegfr3 inhibitors
05/02/2008CA2664145A1 Use of a mt kinase inhibitor for treating or preventing brain cancer
05/02/2008CA2664143A1 Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
05/02/2008CA2664141A1 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds
05/02/2008CA2664115A1 New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90
05/02/2008CA2648243A1 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
05/02/2008CA2647329A1 Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno(2,3-d)pyrimidine
05/02/2008CA2645823A1 Transdermal therapeutic system comprising norelgestromin for contraception and hormone replacement
05/02/2008CA2644929A1 Somatostatin agonists
05/02/2008CA2631024A1 Anthranilic acid derivatives useful in treating infection with hepatitis c virus
05/01/2008US20080103320 Total Synthesis of Myriaporones
05/01/2008US20080103304 Non-nucleotide composition and method for inhibiting platelet aggregation
05/01/2008US20080103213 Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic agents; parenteral colloidal drug delivery system providing improved bioavailability
05/01/2008US20080103211 Poly(divinylbenzene-styrene)sulfonic acid and levobetaxolol; glaucoma
05/01/2008US20080103210 wide spectrum disinfectant
05/01/2008US20080103209 Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
05/01/2008US20080103208 Poly(ADP-ribose) polymerase inhibitor is preferably 3-nitro-4-iodobenzamide; administered orally, topically, parenerally, transdermally, or rectally; anticarcinogenic and antidiabetic agents; obesity, cardiovascular disease
05/01/2008US20080103207 Topical ceramide compositions and methods of use
05/01/2008US20080103206 Synergistic analgesics, antipyretics, and non-steroidal antiinflammatory agents; other oral dosage forms may include a third analgesic; side effect reduction
05/01/2008US20080103205 Treating a crop or farm animal with an anion transport blocker selected from 4,4'-diisothiocyanato-2,2'-stilbenedisulfonic acid, 5-nitro-2-(3-phenylpropylamino)benzoic acid, Anthracene-9-carboxylic acid, and (2-cyclopenyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid; in vivo nematocides
05/01/2008US20080103204 Upregulating or downregulating microglial cells which synthesize nitric oxide; 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid; Parkinson's, Alzheimer's Diseases, AIDS
05/01/2008US20080103203 Skin disinfectant
05/01/2008US20080103202 increasing creatine functionality and bioavailability in mammalian muscle, enhancing solubility and taste, enhancing athletic performance and lean body mass; is prepared at a temperature from 60 to 300 degrees C in a water or organic solution, or without any solvent
05/01/2008US20080103201 Novel alpha-Glucosidase inhibitor from Tabernaemontana dichotoma
05/01/2008US20080103200 Levodopa prodrugs, and compositions and uses thereof
05/01/2008US20080103199 2chlorophenyl-2hydroethyl-carbomate; Autistic, Asperger's, Childhood Disintegrative, Rett's Disorders, and PDD-Not Otherwise Specified; sensory integration problems, (non) verbal communication, social interactions; improve impulse control; inhibit isolation-induced aggressive behavior; co-therapy
05/01/2008US20080103198 2-chlorophenyl-2-hydroethyl-carbamate; neuroprotective agent; otoprotection from damage to neural tissue and cells of the mammalian inner ear from neural injury or insult and from neurotoxic or ototoxic agents; loss of hearing and balance impairments
05/01/2008US20080103197 Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics
05/01/2008US20080103196 19-hydroxylabda-8(17)-en-16,15-olide; mushroom extraction; MTT assay; neuroprotectant; cortical neuron damages, Alzheimer's disease; analgesic, antiinflammatory,anticarcinogenic, hypotensive agent
05/01/2008US20080103195 Compounds from antrodia camphorata for inhibiting the growth of cancer tumor cells